Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
DNA cross-link repair 1A protein (DCLRE1A, also known as SNM1A) is a highly conserved 5′–3′ exonuclease that plays a critical role in the repair of DNA interstrand cross-links (ICLs), structures that physically block DNA replication and transcription. DCLRE1A works with other DNA repair enzymes, particularly the XPF–ERCC1 complex, to unhook and process cross-linked DNA and is integral to maintaining genomic stability during cell division. Loss or reduction of DCLRE1A activity compromises genome integrity, sensitizes cells to DNA-damaging agents (such as cisplatin and mitomycin C), and has been implicated in rare hereditary diseases and cancer predisposition. Alternative splicing produces multiple transcript variants; DCLRE1A is a target for potential chemotherapeutic sensitization strategies and is also studied as a biomarker in DNA repair research.
Sensitization to DNA cross-linking chemotherapeutics by inhibiting DNA repair. Potential for increased cytotoxicity in combination with DNA-damaging agents (e.g., platinum compounds).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on DNA cross-link repair 1A protein (DCLRE1A).